Investing.com - Intellia Therapeutics Inc reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Intellia Therapeutics Inc announced earnings per share of $-1.49 on revenue of $13.27M. Analysts polled by Investing.com EPS of $-1.29 on revenue of $11.43M.
Intellia Therapeutics Inc 's are down 39.61% and is trading at $52.11 , still down 64.92% from its 52 week high of $143.92 set on Monday, November 8, 2021.
Intellia Therapeutics Inc shares gained 3.23% to trade at $52.11 in pre-market trade the report.
Intellia Therapeutics Inc follows other major Healthcare sector earnings this month
Intellia Therapeutics Inc's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.9B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar